CytomX Therapeutics, Inc. beat EPS estimates 38% of the time across 16 reported quarters (6 beats, 10 misses), averaging -11.3% versus consensus. Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result | Call |
|---|---|---|---|---|---|
| Q2 FY26 | $-0.11 | $-0.09 | +18.2% | Beat | Q2 FY26 call |
| Q1 FY26 | $-0.14 | $-0.10 | +28.6% | Beat | |
| Q4 FY25 | not reported | $-0.22 | not reported | not reported | |
| Q3 FY25 | $-0.04 | $-0.09 | -125.0% | Miss | |
| Q2 FY25 | $-0.06 | $0.00 | +100.0% | Beat | |
| Q1 FY25 | $0.18 | $0.27 | +50.0% | Beat | |
| Q4 FY24 | not reported | $0.22 | not reported | not reported | |
| Q3 FY24 | not reported | $0.07 | not reported | not reported | |
| Q2 FY24 | $-0.07 | $-0.08 | -14.3% | Miss | |
| Q1 FY24 | not reported | $0.17 | not reported | not reported | |
| Q4 FY23 | $0.02 | $0.01 | -50.0% | Miss | |
| Q3 FY23 | not reported | $0.04 | not reported | not reported |
Back to CTMX overview · CTMX holders · CTMX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.